REGINA MCDADE: Open Payments
NPI 1174208169 · LEAWOOD, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 41 payments from 13 companies in 2025. Trend: 2023 $15 · 2024 $247 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| JAZZ PHARMACEUTICALS INC. | 8 | $199 |
| GlaxoSmithKline, LLC. | 7 | $154 |
| Melinta Therapeutics, LLC | 6 | $94 |
| AstraZeneca Pharmaceuticals LP | 5 | $82 |
| ABBVIE INC. | 4 | $78 |
| Grifols USA, LLC | 2 | $56 |
| GENZYME CORPORATION | 2 | $38 |
| Verona Pharma, Inc. | 2 | $35 |
| Paratek Pharmaceuticals, Inc. | 1 | $28 |
| Philips North America LLC | 1 | $26 |
Products named: XYWAV, NUCALA, Kimyrsa, DALVANCE, Prolastin-C Liquid, DUPIXENT, Ohtuvayre, FASENRA.
Industry payments across KS — which companies pay providers there.
